Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
What will we expect from novel therapies for oesophageal and gastric malignancies?

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 466
Rating:

Prof Ramon De Mello - University of Algarve, Faro, Portugal

Dr De Mello speaks with ecancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the changing landscape of care and treatment for oesophageal and upper gastric cancers.

He highlights the impact of immuno-oncology seen in gastric cancers, as in many other sites, and the identification of biomarkers to guide targeted therapies.

Among these, Dr De Mello notes the failure of combining ATM targeted therapy and olaparib in a phase III trial, the promising prospect of Tumour Mutational Burden as a prognostic marker, and that management of gastric/oesophageal malignancies is increasingly important in many parts of the world.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation